Document is current
Any future updates will be listed below
-
Authors
Khalil, Nicole https://orcid.org/0009-0007-2332-3557
Kagan, Tomer https://orcid.org/0000-0002-3983-6687
Yosipovitch, Gil https://orcid.org/0000-0001-6303-1822
- License Information
-
More Information
Article History
Received: 29 October 2025
Accepted: 29 January 2026
First Online: 19 February 2026
Declarations
:
: Dr. Gil Yosipovitch serves as an advisory board member for Arcutis Biotherapeutics, AbbVie, Eli Lilly, Galderma, GSK, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc, Sanofi, Escient, and Merck Vifor. Dr. Gil Yosipovitch receives grants/research funding from Regeneron Pharmaceuticals, Inc and Sanofi. Dr. Gil Yosipovitch is an investigator for Pfizer, Eli Lilly, Novartis, Escient, and Sanofi. Nicole Khalil and Tomer Kagan have no conflicts of interest to disclose.
: Dr. Gil Yosipovitch serves as an advisory board member for Arcutis Biotherapeutics, AbbVie, Eli Lilly, Galderma, GSK, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc, Sanofi, Escient, and Merck Vifor. Dr. Gil Yosipovitch receives grants/research funding from Regeneron Pharmaceuticals, Inc and Sanofi. Dr. Gil Yosipovitch is an investigator for Pfizer, Eli Lilly, Novartis, Escient, and Sanofi. Nicole Khalil and Tomer Kagan have no conflicts of interest to disclose.
: This study does not contain any studies with human or animal subjects performed by any of the authors.
